Drug Profile
BMS 986158
Alternative Names: BET inhibitor - Bristol-Myers Squibb; BMS-986158Latest Information Update: 25 Jan 2024
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics; Indoles; Propanols; Pyridines; Small molecules; Triazoles
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Solid tumours
- Phase I/II Multiple myeloma; Myelofibrosis
Most Recent Events
- 09 Dec 2023 Efficacy and adverse events data from phase-Ib/II trial in Myelofibrosis presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 08 Jun 2023 Efficacy and adverse events data from a phase-I/II clinical trial in Myelofibrosis presented at the 28th Congress of the European Haematology Association (EHA-2023)
- 10 Dec 2022 Safety and efficacy data from a phase I/II trial in Myelofibrosis presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)